Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

Inclusion Criteria

• •Patients ages 18-70
• •Underlying hematological disorder which is potentially curable with allogeneic bone marrow transplantation. This includes, but is not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), AL amyloidosis, diamond blackfan anemia, myelofibrosis or other myeloproliferative disease, sickle cell anemia, and thalassemia.
• •Existence of haploidentical first degree relative who passes standard donor evaluations for bone marrow and kidney donation
• •LVEF \> 40% as measured by echocardiography or MUGA
• •FEV1, FVC, and DLCO \> 50% of predicted as measured by standard PFTs
• •Total bilirubin \< 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all \< 5x institutions upper limit of normal
• •ABO compatibility in the host vs. graft direction
• •Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant.
• •Participants should be on dialysis or have an estimated or measured CrCl \< 35 ml/min
• •Life expectancy greater than six months.
• •Recipient ability to understand and provide informed consent